{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:18:14Z","timestamp":1788347894866,"version":"build-2803163510"},"reference-count":51,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T00:00:00Z","timestamp":1503532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Delayed, large\u2010volume bacterial culture and amotosalen\/ultraviolet\u2010A light pathogen reduction are effective at reducing the risk of bacterial proliferation in platelet concentrates (PCs). Hemovigilance programs continue to receive reports of suspected septic transfusion reactions, most with low imputability. Here, we compile national hemovigilance data to determine the relative efficacy of these interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Annual reports from the United Kingdom, France, Switzerland, and Belgium were reviewed between 2005 and 2016 to assess the risk of bacterial contamination and septic reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Approximately 1.65 million delayed, large\u2010volume bacterial culture\u2010screened PCs in the United Kingdom and 2.3 million amotosalen\/ultraviolet\u2010A\u2013treated PCs worldwide were issued with no reported septic fatalities. One definite, one possible, and 12 undetermined\/indeterminate septic reactions and eight contaminated \u201cnear misses\u201d were reported with delayed, large\u2010volume bacterial cultures between 2011 and 2016, for a lower false\u2010negative culture rate than that in the previous 5 years (5.4 vs. 16.3 per million: odds ratio, 3.0; 95% confidence interval, 1.4\u20106.5). Together, the Belgian, Swiss, and French hemovigilance programs documented zero probable or definite\/certain septic reactions with 609,290 amotosalen\/ultraviolet\u2010A\u2013treated PCs (&lt;1.6 per million). The rates were significantly lower than those reported with concurrently transfused, nonpathogen\u2010reduced PCs in Belgium (&lt;4.4 vs. 35.6 per million: odds ratio, 8.1; 95% confidence interval,1.1\u2010353.3) and with historic septic reaction rates in Switzerland (&lt;6.0 vs. 82.9 per million: odds ratio, 13.9; 95% confidence interval, 2.1\u2010589.2), and the rates tended to be lower than those from concurrently transfused, nonpathogen\u2010reduced PCs in France (&lt;4.7 vs. 19.0 per million: odds ratio, 4.1; 95% confidence interval, 0.7\u2010164.3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Pathogen reduction and bacterial culture both reduced the incidence of septic reactions, although under\u2010reporting and strict imputability criteria resulted in an underestimation of risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/trf.14284","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:07:45Z","timestamp":1503619665000},"page":"2946-2957","source":"Crossref","is-referenced-by-count":66,"title":["Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems"],"prefix":"10.1111","volume":"57","author":[{"given":"Richard J.","family":"Benjamin","sequence":"first","affiliation":[{"name":"Cerus Corporation Concord California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Braschler","sequence":"additional","affiliation":[{"name":"Luzerner Kantonsspital Luzern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Weingand","sequence":"additional","affiliation":[{"name":"Blutspendedienst Zentralschweiz SRK Luzern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence M.","family":"Corash","sequence":"additional","affiliation":[{"name":"Cerus Corporation Concord California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2014.01.001"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357651"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12603"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12148"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03308.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00581-X"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2015.08.004"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02694.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14042"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4443"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12287"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13530"},{"key":"e_1_2_7_14_1","article-title":"Evaluation of the Mirasol pathogen inactivation system as an alternative to bacterial screening of platelet components","volume":"111","author":"McDonald CP","year":"2016","journal-title":"Vox Sang"},{"key":"e_1_2_7_15_1","article-title":"Evaluation of the Cerus INTERCEPT pathogen inactivation system as an alternative to bacterial screening of platelet components","volume":"111","author":"Allen J","year":"2016","journal-title":"Vox Sang"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12158"},{"key":"e_1_2_7_17_1","first-page":"176","article-title":"The first year of bacterial screening of platelet components\u2014the English experience","volume":"103","author":"McDonald C","year":"2012","journal-title":"Vox Sang"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01132.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14085"},{"key":"e_1_2_7_20_1","first-page":"653","article-title":"Pseudomonas cepacia infections caused by thawing cryoprecipitate in a contaminated water bath (abstract)","volume":"19","author":"Rhame FS","year":"1979","journal-title":"Transfusion"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03530.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03083.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2006.05.002"},{"key":"e_1_2_7_24_1","unstructured":"Serious Hazards of Transfusion (SHOT). Serious Hazards of Transfusion annual reports and summaries 1996\u20102015 [cited2017Jun 20]. Available from:https:\/\/www.shotuk.org\/shot-reports\/"},{"key":"e_1_2_7_25_1","unstructured":"Swissmedic. Hemovigilance annual reports 2003\u20102014 [cited2017Jun 20]. Available from:https:\/\/www.swissmedic.ch\/marktueberwachung\/00138\/00188\/index.html?lang=en"},{"key":"e_1_2_7_26_1","unstructured":"Federaal Agentschap voor Geneesmiddelen en Gezondsheidsproducten(FAGG). Federaal Agentschap voor Geneesmiddelen en Gezondsheidsproducten Annual Hemovigilance Reports 2006\u20102015 [cited 2017 Jun 20]. Available from:https:\/\/www.fagg-afmps.be\/nl\/MENSELIJK_gebruik\/gezondheidsproducten\/bloed_en_bloedbestanddelen\/hemovigilantie\/jaarverslagen"},{"key":"e_1_2_7_27_1","unstructured":"Centers for Disease Control and Prevention(CDC). National Healthcare Safety Network imputability criteria [cited2017Jun 20]. Available from:http:\/\/www.cdc.gov\/nhsn\/PDFs\/Biovigilance\/Appendix-A-BV-Protocol-1-3-1-June-2011.pdf"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02873.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02111.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12883"},{"key":"e_1_2_7_31_1","unstructured":"Agence Nationale de S\u00e9curit\u00e9 deu M\u00e9 dicament et des Produits de Sant\u00e9(ANSM). Annual Hemovigilance Activity Reports (2001\u20102015) [cited 2017 Jun 20]. Available from:http:\/\/ansm.sante.fr\/Mediatheque\/Publications\/Bilans-Rapports-d-activite-Bilans-et-rapports-d-activite#folder_26762"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12098"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2011.02.023"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2007.01035.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13511"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03735.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2008.01051.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03821.x"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1995.35495216077.x"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38798346637.x"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01326.x"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41040477.x"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02192.x"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.04125.x"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12065"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14198"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-655944"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-685198"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00697"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12410"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13232"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13171"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.14284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T01:53:49Z","timestamp":1694742829000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.14284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,24]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/trf.14284"],"URL":"https:\/\/doi.org\/10.1111\/trf.14284","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.729275438.793569554","asserted-by":"object"}]},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,24]]}}}